Search
oritavancin (Novocid)
Indications:
- acute gram-positive bacterial skin infections
Dosage:
- given IV once (once weekly) [3]
Antimicrobial activity:
- Staphylococcus aureus including MRSA
- Streptococcus
- Streptococcus pyogenes
- Streptococcus agalactiae
- Streptococcus anginosus
- Enterococcus faecalis
Adverse effects:
- nausea, headache, diarrhea
- elevations of serum transaminases
- red man syndrome
Mechanism of action:
- inhibition of bacterial cell wall formation (by analogy to dalbavancin)
Notes:
- FDA-approved August 2014 [2]
General
antibacterial glycopeptide
aromatic compound
Database Correlations
PUBCHEM correlations
References
- Corey GR et al.
Single-dose oritavancin in the treatment of acute bacterial
skin infections.
N Engl J Med 2014 Jun 5; 370:2180.
PMID: 24897083
http://www.nejm.org/doi/full/10.1056/NEJMoa1310422
- FDA News Release. August 6, 2014
FDA approves Orbactiv to treat skin infections
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015